Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
2
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Propanc Biopharma Inc market cap is $5.17M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Propanc Biopharma Inc 52 week high is $270.25 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Propanc Biopharma Inc 52 week low is $1.30 as of November 18, 2026.
Propanc Biopharma Inc stock price today is $2.18.
Propanc Biopharma Inc stock price yesterday was $2.27.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Propanc Biopharma Inc's P/E ratio is -0.06.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Propanc Biopharma Inc P/B ratio is 0.1913.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Propanc Biopharma Inc 50-day moving average is $2.25.